Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The company worked to respond to growing demand for generic drugs, pass higher costs through to selling prices, expand its product lineup, and strengthen its production and supply systems. Discontinued operations resulted in an interim loss of ¥998 million, including a ¥955 million loss on the sale of shares in an affiliated company associated with the transfer of the US business.
None
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | 102,019 Millions of yen (YoY +3.2%) |
| Operating profit | 9,595 Millions of yen (YoY +12.4%) |
| Ordinary income | 8,630 Millions of yen (YoY +8.4%) |
| Profit attributable to owners of the parent | 4,926 Millions of yen (YoY -15.7%) |
| Net income per share | ¥42.62 |
| Equity ratio | End of the current fiscal period 47.4 / End of previous period 49.6 |
| Total assets | 380,396 Millions of yen |
| Net assets | 180,197 Millions of yen |
| Cash flows from operating activities | 1,233 Millions of yen |
| Cash flows from investing activities | -18,318 Millions of yen |
| Cash flows from financing activities | 16,849 Millions of yen |
| Cash and cash equivalents at end of period | 28,744 Millions of yen |
| Full-year earnings forecast | Net Sales 212,700 Millions of yen (YoY +5.5%) / Operating profit 22,900 Millions of yen (YoY +44.1%) / Ordinary income 20,900 Millions of yen (YoY +46.4%) / Net income 13,700 Millions of yen (YoY +31.3%) |
| Revision to Earnings Forecast | None |
| Annual Dividend Forecast | 55 Yen → 56 Yen |
| Depreciation and amortization | 8,795 Millions of yen |
| Impairment loss | Amount 748 Millions of yen / Subject assets Not disclosed |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 115,685,926 |
| Treasury Shares at Period-End | 1,503 |
| Factors Behind Changes in Business Performance | The company worked to respond to growing demand for generic drugs, pass higher costs through to selling prices, expand its product lineup, and strengthen its production and supply systems. Discontinued operations resulted in an interim loss of ¥998 million, including a ¥955 million loss on the sale of shares in an affiliated company associated with the transfer of the US business. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company described initiatives including responding to growing demand for generic drugs, passing higher costs through to selling prices, expanding its product lineup, and strengthening its production and supply systems. Profit attributable to owners of the parent includes an interim loss of ¥998 million from discontinued operations, including a ¥955 million loss on the sale of shares in an affiliated company.